View ValuationAcorda Therapeutics 将来の成長Future 基準チェック /06現在、 Acorda Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Nov 15Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. provides revenue guidance for the full year 2023. For the full year 2023, the Company reaffirms INBRIJA U.S. net revenue guidance to be $34-$38 million and AMPYRA net revenue guidance to be $65-$70 million.お知らせ • Aug 11Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.お知らせ • May 12Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.Major Estimate Revision • Mar 11Analysts increase revenue estimates to US$95.7mThe 2021 consensus revenue estimate increased from US$64.5m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$14.61 to -US$12.17 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target increased from US$4.00 to US$5.00. Share price is down by 14% to US$5.39 over the past week.Price Target Changed • Feb 05Price target lowered to US$19.50Down from US$22.00, the current price target is an average from 3 analysts. The new target price is 172% above the current share price of US$7.16. As of last close, the stock is down 43% over the past year.Major Estimate Revision • Jan 15Analysts increase EPS estimates to -US$2.88The 2020 consensus revenue estimate increased from US$133.1m to US$139.5m. Analysts raised their EPS forecasts from -US$4.95 to -US$2.88 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 11% next year. The consensus price target increased from US$22.00 to US$23.00. Share price is up 53% to US$6.37 over the past week.すべての更新を表示Recent updatesお知らせ • Aug 14First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Acorda Therapeutics, Inc. on August 13, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e. up to September 30, 2024, and November 29, 2024, respectively.お知らせ • Aug 13Acorda Therapeutics Files Form 15Acorda Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share.お知らせ • Jul 12Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. The acquisition is subjected to the approval by regulatory board, court approval and antitrust regulations. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Scott Talmadge, Adam Golden, Sarah Ghulamhussain, Christopher Stothers, Jenny Leahy, Meghan Rissmiller, Aimen Mir, Stephanie Brown Cripps, Christine Lyon, Joe Soltis, Brock DahlGian Luca Zampa and Sanjay Murti of Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics. As on June 12, 2024 the transaction has been approved by the court. Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. on July 10, 2024.お知らせ • Jul 04Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.The US Bankruptcy Court approved the solicitation version of the first amended disclosure statement of Acorda Therapeutics, Inc. on July 3, 2024. The debtor had filed its solicitation version of amended disclosure statement in the Court on July 2, 2024. June 28, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is July 31, 2024. The confirmation hearing for the plan has been scheduled for August 7, 2024.お知らせ • Apr 27Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the ‘Company’) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (‘Nasdaq’) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the ‘Common Stock’) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol ‘ACORQ.’ On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which the company’s common stock will remain registered under Section 12(g) of the Exchange Act.お知らせ • Apr 17Acorda Therapeutics Announces Delisting from NasdaqAcorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the company’s commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders’ equity of at least $10 million. Trading in the company’s common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company’s common stock is quoted on the OTC Pink Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the ‘ACORQ’ ticker symbol.お知らせ • Apr 12Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite IndexAcorda Therapeutics, Inc removedお知らせ • Apr 05+ 3 more updatesMotion for Asset Sale Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on April 4, 2024. The debtor seeks the Court’s approval for the sale of substantially all its assets to Merz Pharmaceuticals, LLC, the stalking horse bidder, for a purchase price of $185 million in cash, plus the assumption of certain liabilities pursuant to the asset purchase agreement, dated March 31, 2024. The debtor’s assets include substantially all its assets excluding all Cash, including all restricted cash, and any security and utility deposits, escrow deposits, cash collateral, all insurance policies, all shares of capital stock, partnership interests, membership interests or other equity interests of Sellers or any of their Subsidiaries, and all warrants and options for, and other securities exchange for or convertible or exercisable into, all Leases, the Retained Books and Records, all Seller Benefit Plans, all Contracts that are not Assigned Contracts, any Right to any refund or credit with respect to Taxes relating to any Pre-Closing Tax Period, and all proceeds from chargebacks, Rebates, cash discounts and fees for services payable to Sellers from wholesalers, distributors, hospital customers, and payors. To qualify as a qualified bidder, interested parties should submit their bids by May 16, 2024, along with good-faith deposit in the amount of $18.5 million within three business day of execution of this agreement and $5 million at the time of closing. The initial minimum overbid should be at least $11.75 million more than the initial purchase price. The debtor has scheduled an auction on May 22, 2024. At the auction, the subsequent bids would be in increments of $1 million. The stalking horse bidder would be entitled to a break-up fee of 3.5% of the purchase price and expense reimbursement of 1.5% of the purchase price in case of termination of the asset purchase agreement. The sale hearing is scheduled for May 24, 2024, in case no auction takes place and in case auction takes place will be scheduled for May 31, 2024.お知らせ • Apr 03Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics.お知らせ • Apr 02+ 1 more updateMotion for Joint Administration Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on April 1, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Acorda Therapeutics Limited, Biotie Therapies AG, Biotie Therapies, LLC, Civitas Therapeutics, Inc. and Neuronex, Inc., with its own case for administrative and procedural purposes. Acorda Therapeutics, Inc. has been proposed as the lead debtor.お知らせ • Mar 26Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024Acorda Therapeutics, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Apr 01, 2024分析記事 • Feb 21Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Feb 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (US$18.4m market cap).分析記事 • Dec 18Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For ExcitementAcorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53...Reported Earnings • Nov 16Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)Third quarter 2023 results: US$7.16 loss per share (improved from US$11.41 loss in 3Q 2022). Revenue: US$27.7m (down 17% from 3Q 2022). Net loss: US$8.89m (loss narrowed 36% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.お知らせ • Nov 15Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. provides revenue guidance for the full year 2023. For the full year 2023, the Company reaffirms INBRIJA U.S. net revenue guidance to be $34-$38 million and AMPYRA net revenue guidance to be $65-$70 million.お知らせ • Nov 07Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJAAcorda Therapeutics, Inc. announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas). INBRIJA is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease (PD) treated with carbidopa/levodopa. Biopas has submitted for marketing approval of INBRIJA in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings for approval of INBRIJA in Chile in late 2023 and in Mexico and Brazil in 2024.New Risk • Aug 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Market cap is less than US$100m (US$21.1m market cap).お知らせ • Aug 11Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.Reported Earnings • Aug 09Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)Second quarter 2023 results: US$7.55 loss per share (improved from US$55.63 loss in 2Q 2022). Revenue: US$29.7m (down 4.4% from 2Q 2022). Net loss: US$9.38m (loss narrowed 80% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Jun 27Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1). Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.お知らせ • Jun 06Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select MarketAcorda Therapeutics, Inc. announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time June 5, 2023, and the Company's common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023. The reverse stock split was effected to enable the Company to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. On November 11, 2022, the Company's stockholders authorized the board of directors to effect a reverse stock split by a ratio of any whole number in the range of 1-for-2 to 1-for-20 and a corresponding reduction in the number of authorized shares of common stock. The board of directors subsequently approved the reverse stock split and authorized the filing of the Company's amended and restated certificate of incorporation, as previously announced on May 31, 2023.分析記事 • Jun 05Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Jun 02Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued ListingAcorda Therapeutics, Inc. announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 4:01 p.m. Eastern Time, on June 2, 2023. The company’s common stock will begin trading on a post-split basis at the market open on June 5, 2023. The reverse stock split is being effected to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. The reverse stock split will apply equally to all outstanding shares of the common stock, and each stockholder will hold the same percentage of common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares. The Company will not issue any fractional shares in connection with the reverse stock split, and the number of shares issued will be rounded up to the next whole share. The reverse stock split will not modify the rights or preferences of the common stock. As a result of the proportionate reduction in the number of authorized shares of common stock, the reverse stock split will result in the number of authorized shares of common stock being reduced from 61,666,666 to 3,083,333. As previously reported in the company’s Current Report on Form 8-K filed on November 14, 2022, on November 11, 2022, the company’s stockholders approved a proposal to authorize the company’s board of directors to approve an amendment and restatement of the company’s certificate of incorporation to effect a reverse stock split of the company’s common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of the company’s common stock, within one year following the conclusion of the Special Meeting of Stockholders on November 11, 2022.Reported Earnings • May 12First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)First quarter 2023 results: US$0.69 loss per share (improved from US$1.85 loss in 1Q 2022). Revenue: US$22.3m (down 1.2% from 1Q 2022). Net loss: US$16.8m (loss narrowed 31% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.お知らせ • May 12Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.Reported Earnings • Mar 11Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)Full year 2022 results: US$3.35 loss per share (improved from US$9.79 loss in FY 2021). Revenue: US$118.6m (down 8.1% from FY 2021). Net loss: US$65.9m (loss narrowed 37% from FY 2021). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.お知らせ • Feb 16Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that the Nasdaq Hearings Panel has granted the Company's extension request until June 20, 2023 to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. "We are pleased Nasdaq has granted us this extension," said Ron Cohen, M.D., Acorda's President and Chief Executive Officer. "We have announced a detailed business plan and long-term financial guidance to demonstrate what we believe is a path to growing shareholder value in Acorda. The key components of that plan are continued fiscal discipline, growing the Inbrija trajectory, and maintaining the Ampyra brand. We believe that it is in the best interests of our shareholders that we achieve compliance with the bid price rule organically by executing on that plan." If at any time before June 20, 2023 the bid price of Acorda's stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022.Reported Earnings • Nov 18Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 02Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 17Acorda wins $16.5M in Ampyra arbitration case with AlkermesAcorda Therapeutics (NASDAQ:ACOR), a biotech focused on neurological disorders, announced Sunday that a panel of arbitrators awarded it $16.5M from Alkermes (ALKS) in connection with a licensing dispute between the two over multiple sclerosis therapy Ampyra. ACOR shares added ~46% pre-market on Monday in reaction to the news. The decision comes after ACOR sought the intervention of the American Arbitration Association in July 2020 following a dispute with ALKS with the expiration of an Ampyra patent in 2018. The ruling requires ALKS to pay $15M to cover past royalties and $1.5M as prejudgment interest to ACOR. In addition, ACOR will be free to use alternative supplies of Ampyra and will not have to pay ALKS any royalties on net sales for licensing and supplies. Also known as dalfampridine, Ampyra is marketed as Fampyra outside the U.S. by Biogen (BIIB). The extended-release tablet formulation is indicated in the U.S. to improve walking in adults with multiple sclerosis. In 2021, ACOR generated $84.6M of net revenue from Ampyra in the U.S.Seeking Alpha • Oct 10Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on voteAcorda Therapeutics (NASDAQ:ACOR) said it withdrew a proposal requesting to increase the number of company's authorized shares. The company is scheduled to hold a special meeting of stockholders on Nov. 4, where several proposals would be put to vote. Meanwhile, a proposal for authorization of a reverse stock split remains on the ballot and the board has asked the shareholders to vote in favor of the request, the company said in an Oct. 10 press release. "However, the proposal to implement a reverse split of Acorda's stock remains critical to ensure that we can get the stock price above $1.00, which would prevent the company from being delisted by Nasdaq. If that were to occur, we could be in default on our obligations to our debtholders and may be required to declare bankruptcy or liquidate, which would be adverse to the interests of shareholders and patients," said Acorda's President and CEO Ron Cohen. ACOR +10.81% to $0.41 premarket Oct. 10Seeking Alpha • Aug 29Acorda inks license deal with Asieris for pre-clinical drugCommercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses. In return, Acorda (ACOR) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales. Acorda (ACOR) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat. Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.Seeking Alpha • Aug 19Acorda Therapeutics announces resignation of COOAcorda Therapeutics (NASDAQ:ACOR) has announced that Lauren Sabella, Chief Operating Officer, will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior VP, Operations & Strategic Planning and Susan Way, Senior VP, Drug Development and Regulatory Affairs. ACOR +4.35% premarket to $0.48.Reported Earnings • Aug 05Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)Second quarter 2022 results: US$2.78 loss per share (down from US$2.29 loss in 2Q 2021). Revenue: US$31.1m (down 2.3% from 2Q 2021). Net loss: US$46.7m (loss widened 104% from 2Q 2021).Reported Earnings • May 13First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: US$1.93 loss per share (up from US$3.53 loss in 1Q 2021). Revenue: US$22.5m (down 22% from 1Q 2021). Net loss: US$25.6m (loss narrowed 24% from 1Q 2021). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 56%.Board Change • May 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 11Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$9.95 loss per share (up from US$12.32 loss in FY 2020). Revenue: US$129.1m (down 16% from FY 2020). Net loss: US$104.0m (loss widened 4.4% from FY 2020). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 56%.Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: US$31.5m (down 41% from 3Q 2020). Net loss: US$27.1m (down 468% from profit in 3Q 2020).Seeking Alpha • Oct 04Acorda Therapeutics: Managing The TransitionToday, we take our first look at Acorda Therapeutics which has two approved products on the market. One of these is seeing increasing generic competition while the other is ramping up sales. The company recently announced a significant workforce reduction to reduce costs. Can Acorda manage this transition without diluting shareholders? A full investment analysis follows in the paragraphs below.Executive Departure • Aug 26Independent Director Barry Greene has left the companyOn the 20th of August, Barry Greene's tenure as Independent Director ended after 14.6 years in the role. As of June 2021, Barry still personally held only 213.00 shares (US$1.0k worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.Executive Departure • Aug 26Independent Director Catherine D. Strader has left the companyOn the 22nd of August, Catherine D. Strader's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Catherine D.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.Reported Earnings • Aug 09Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$31.8m (down 5.5% from 2Q 2020). Net loss: US$22.9m (loss widened 31% from 2Q 2020).Seeking Alpha • Jul 24Acorda Therapeutics Continues To Maneuver For A TurnaroundAcorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years. The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket. Acorda was able to remove their debt that was due in 2021. Now, with that overhang removed, any progress made should be reflected in the share price. I update my plan for trading Acorda over the remainder of 2021 as we wait for the remaining quarterly earnings.分析記事 • May 26Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For NowThe underwhelming share price performance of Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) in the past three years would...Reported Earnings • May 09First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$28.9m (up 2.7% from 1Q 2020). Net loss: US$33.5m (loss widened 417% from 1Q 2020).Major Estimate Revision • Mar 11Analysts increase revenue estimates to US$95.7mThe 2021 consensus revenue estimate increased from US$64.5m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$14.61 to -US$12.17 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target increased from US$4.00 to US$5.00. Share price is down by 14% to US$5.39 over the past week.分析記事 • Mar 09Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their ForecastsAcorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders will have a reason to smile today, with the covering analyst...Reported Earnings • Mar 06Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$153.0m (down 21% from FY 2019). Net loss: US$99.6m (loss narrowed 64% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 68% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 06Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 153%. Over the next year, revenue is expected to shrink by 58% compared to a 1,454% growth forecast for the Biotechs industry in the US.Price Target Changed • Feb 05Price target lowered to US$19.50Down from US$22.00, the current price target is an average from 3 analysts. The new target price is 172% above the current share price of US$7.16. As of last close, the stock is down 43% over the past year.Is New 90 Day High Low • Jan 15New 90-day high: US$6.70The company is up 67% from its price of US$4.01 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.Major Estimate Revision • Jan 15Analysts increase EPS estimates to -US$2.88The 2020 consensus revenue estimate increased from US$133.1m to US$139.5m. Analysts raised their EPS forecasts from -US$4.95 to -US$2.88 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 11% next year. The consensus price target increased from US$22.00 to US$23.00. Share price is up 53% to US$6.37 over the past week. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Acorda Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ACOR.Q - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2024116-263-27-27N/A12/31/2023118-253-14-14N/A9/30/2023111-16-2-2N/A6/30/2023117-21-11-11N/A3/31/2023118-58-14-14N/A12/31/2022119-66-21-21N/A9/30/2022124-106-27-27N/A6/30/2022122-119-34-34N/A3/31/2022123-95-28-28N/A12/31/2021129-104-42-41N/A9/30/2021130-166-44-43N/A6/30/2021152-132-37-37N/A3/31/2021154-127-51-49N/A12/31/2020153-100-65-61N/A9/30/202016549-92-74N/A6/30/2020160-222-133-95N/A3/31/2020176-232-157-89N/A12/31/2019192-273-219-128N/A9/30/2019211-329-216-129N/A6/30/2019306-79-107-27N/A3/31/2019409-6-945N/A12/31/201847134117151N/A9/30/2018591-147197224N/A6/30/2018589-158181197N/A3/31/2018575-213138151N/A12/31/2017588-223N/A97N/A9/30/2017541-55N/A69N/A6/30/2017535-43N/A23N/A3/31/2017523-53N/A3N/A12/31/2016520-35N/A30N/A9/30/2016510-22N/A25N/A6/30/2016522-6N/A42N/A3/31/201650914N/A54N/A12/31/201549311N/A38N/A9/30/20154802N/A29N/A6/30/201543710N/A46N/A3/31/201542114N/A61N/A12/31/201440118N/A75N/A9/30/201437624N/A81N/A6/30/201435519N/A62N/A3/31/201434518N/A51N/A12/31/201333616N/A39N/A9/30/2013325143N/A37N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ACOR.Qの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ACOR.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ACOR.Qの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ACOR.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ACOR.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ACOR.Qの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/13 21:33終値2024/08/13 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Acorda Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Robert LeBoyerAegis Capital CorporationChristopher RaymondBairdKenneth TrbovichBrean Capital Historical (Janney Montgomery)17 その他のアナリストを表示
お知らせ • Nov 15Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. provides revenue guidance for the full year 2023. For the full year 2023, the Company reaffirms INBRIJA U.S. net revenue guidance to be $34-$38 million and AMPYRA net revenue guidance to be $65-$70 million.
お知らせ • Aug 11Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.
お知らせ • May 12Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.
Major Estimate Revision • Mar 11Analysts increase revenue estimates to US$95.7mThe 2021 consensus revenue estimate increased from US$64.5m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$14.61 to -US$12.17 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target increased from US$4.00 to US$5.00. Share price is down by 14% to US$5.39 over the past week.
Price Target Changed • Feb 05Price target lowered to US$19.50Down from US$22.00, the current price target is an average from 3 analysts. The new target price is 172% above the current share price of US$7.16. As of last close, the stock is down 43% over the past year.
Major Estimate Revision • Jan 15Analysts increase EPS estimates to -US$2.88The 2020 consensus revenue estimate increased from US$133.1m to US$139.5m. Analysts raised their EPS forecasts from -US$4.95 to -US$2.88 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 11% next year. The consensus price target increased from US$22.00 to US$23.00. Share price is up 53% to US$6.37 over the past week.
お知らせ • Aug 14First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Acorda Therapeutics, Inc. on August 13, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e. up to September 30, 2024, and November 29, 2024, respectively.
お知らせ • Aug 13Acorda Therapeutics Files Form 15Acorda Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share.
お知らせ • Jul 12Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. The acquisition is subjected to the approval by regulatory board, court approval and antitrust regulations. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Scott Talmadge, Adam Golden, Sarah Ghulamhussain, Christopher Stothers, Jenny Leahy, Meghan Rissmiller, Aimen Mir, Stephanie Brown Cripps, Christine Lyon, Joe Soltis, Brock DahlGian Luca Zampa and Sanjay Murti of Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics. As on June 12, 2024 the transaction has been approved by the court. Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. on July 10, 2024.
お知らせ • Jul 04Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.The US Bankruptcy Court approved the solicitation version of the first amended disclosure statement of Acorda Therapeutics, Inc. on July 3, 2024. The debtor had filed its solicitation version of amended disclosure statement in the Court on July 2, 2024. June 28, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is July 31, 2024. The confirmation hearing for the plan has been scheduled for August 7, 2024.
お知らせ • Apr 27Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the ‘Company’) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (‘Nasdaq’) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the ‘Common Stock’) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol ‘ACORQ.’ On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which the company’s common stock will remain registered under Section 12(g) of the Exchange Act.
お知らせ • Apr 17Acorda Therapeutics Announces Delisting from NasdaqAcorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the company’s commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders’ equity of at least $10 million. Trading in the company’s common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company’s common stock is quoted on the OTC Pink Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the ‘ACORQ’ ticker symbol.
お知らせ • Apr 12Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite IndexAcorda Therapeutics, Inc removed
お知らせ • Apr 05+ 3 more updatesMotion for Asset Sale Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on April 4, 2024. The debtor seeks the Court’s approval for the sale of substantially all its assets to Merz Pharmaceuticals, LLC, the stalking horse bidder, for a purchase price of $185 million in cash, plus the assumption of certain liabilities pursuant to the asset purchase agreement, dated March 31, 2024. The debtor’s assets include substantially all its assets excluding all Cash, including all restricted cash, and any security and utility deposits, escrow deposits, cash collateral, all insurance policies, all shares of capital stock, partnership interests, membership interests or other equity interests of Sellers or any of their Subsidiaries, and all warrants and options for, and other securities exchange for or convertible or exercisable into, all Leases, the Retained Books and Records, all Seller Benefit Plans, all Contracts that are not Assigned Contracts, any Right to any refund or credit with respect to Taxes relating to any Pre-Closing Tax Period, and all proceeds from chargebacks, Rebates, cash discounts and fees for services payable to Sellers from wholesalers, distributors, hospital customers, and payors. To qualify as a qualified bidder, interested parties should submit their bids by May 16, 2024, along with good-faith deposit in the amount of $18.5 million within three business day of execution of this agreement and $5 million at the time of closing. The initial minimum overbid should be at least $11.75 million more than the initial purchase price. The debtor has scheduled an auction on May 22, 2024. At the auction, the subsequent bids would be in increments of $1 million. The stalking horse bidder would be entitled to a break-up fee of 3.5% of the purchase price and expense reimbursement of 1.5% of the purchase price in case of termination of the asset purchase agreement. The sale hearing is scheduled for May 24, 2024, in case no auction takes place and in case auction takes place will be scheduled for May 31, 2024.
お知らせ • Apr 03Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics.
お知らせ • Apr 02+ 1 more updateMotion for Joint Administration Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on April 1, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Acorda Therapeutics Limited, Biotie Therapies AG, Biotie Therapies, LLC, Civitas Therapeutics, Inc. and Neuronex, Inc., with its own case for administrative and procedural purposes. Acorda Therapeutics, Inc. has been proposed as the lead debtor.
お知らせ • Mar 26Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024Acorda Therapeutics, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Apr 01, 2024
分析記事 • Feb 21Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Feb 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (US$18.4m market cap).
分析記事 • Dec 18Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For ExcitementAcorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53...
Reported Earnings • Nov 16Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)Third quarter 2023 results: US$7.16 loss per share (improved from US$11.41 loss in 3Q 2022). Revenue: US$27.7m (down 17% from 3Q 2022). Net loss: US$8.89m (loss narrowed 36% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
お知らせ • Nov 15Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. provides revenue guidance for the full year 2023. For the full year 2023, the Company reaffirms INBRIJA U.S. net revenue guidance to be $34-$38 million and AMPYRA net revenue guidance to be $65-$70 million.
お知らせ • Nov 07Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJAAcorda Therapeutics, Inc. announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas). INBRIJA is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease (PD) treated with carbidopa/levodopa. Biopas has submitted for marketing approval of INBRIJA in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings for approval of INBRIJA in Chile in late 2023 and in Mexico and Brazil in 2024.
New Risk • Aug 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Market cap is less than US$100m (US$21.1m market cap).
お知らせ • Aug 11Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.
Reported Earnings • Aug 09Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)Second quarter 2023 results: US$7.55 loss per share (improved from US$55.63 loss in 2Q 2022). Revenue: US$29.7m (down 4.4% from 2Q 2022). Net loss: US$9.38m (loss narrowed 80% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Jun 27Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1). Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.
お知らせ • Jun 06Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select MarketAcorda Therapeutics, Inc. announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time June 5, 2023, and the Company's common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023. The reverse stock split was effected to enable the Company to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. On November 11, 2022, the Company's stockholders authorized the board of directors to effect a reverse stock split by a ratio of any whole number in the range of 1-for-2 to 1-for-20 and a corresponding reduction in the number of authorized shares of common stock. The board of directors subsequently approved the reverse stock split and authorized the filing of the Company's amended and restated certificate of incorporation, as previously announced on May 31, 2023.
分析記事 • Jun 05Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Jun 02Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued ListingAcorda Therapeutics, Inc. announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 4:01 p.m. Eastern Time, on June 2, 2023. The company’s common stock will begin trading on a post-split basis at the market open on June 5, 2023. The reverse stock split is being effected to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. The reverse stock split will apply equally to all outstanding shares of the common stock, and each stockholder will hold the same percentage of common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares. The Company will not issue any fractional shares in connection with the reverse stock split, and the number of shares issued will be rounded up to the next whole share. The reverse stock split will not modify the rights or preferences of the common stock. As a result of the proportionate reduction in the number of authorized shares of common stock, the reverse stock split will result in the number of authorized shares of common stock being reduced from 61,666,666 to 3,083,333. As previously reported in the company’s Current Report on Form 8-K filed on November 14, 2022, on November 11, 2022, the company’s stockholders approved a proposal to authorize the company’s board of directors to approve an amendment and restatement of the company’s certificate of incorporation to effect a reverse stock split of the company’s common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of the company’s common stock, within one year following the conclusion of the Special Meeting of Stockholders on November 11, 2022.
Reported Earnings • May 12First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)First quarter 2023 results: US$0.69 loss per share (improved from US$1.85 loss in 1Q 2022). Revenue: US$22.3m (down 1.2% from 1Q 2022). Net loss: US$16.8m (loss narrowed 31% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
お知らせ • May 12Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.
Reported Earnings • Mar 11Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)Full year 2022 results: US$3.35 loss per share (improved from US$9.79 loss in FY 2021). Revenue: US$118.6m (down 8.1% from FY 2021). Net loss: US$65.9m (loss narrowed 37% from FY 2021). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that the Nasdaq Hearings Panel has granted the Company's extension request until June 20, 2023 to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. "We are pleased Nasdaq has granted us this extension," said Ron Cohen, M.D., Acorda's President and Chief Executive Officer. "We have announced a detailed business plan and long-term financial guidance to demonstrate what we believe is a path to growing shareholder value in Acorda. The key components of that plan are continued fiscal discipline, growing the Inbrija trajectory, and maintaining the Ampyra brand. We believe that it is in the best interests of our shareholders that we achieve compliance with the bid price rule organically by executing on that plan." If at any time before June 20, 2023 the bid price of Acorda's stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022.
Reported Earnings • Nov 18Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 02Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 17Acorda wins $16.5M in Ampyra arbitration case with AlkermesAcorda Therapeutics (NASDAQ:ACOR), a biotech focused on neurological disorders, announced Sunday that a panel of arbitrators awarded it $16.5M from Alkermes (ALKS) in connection with a licensing dispute between the two over multiple sclerosis therapy Ampyra. ACOR shares added ~46% pre-market on Monday in reaction to the news. The decision comes after ACOR sought the intervention of the American Arbitration Association in July 2020 following a dispute with ALKS with the expiration of an Ampyra patent in 2018. The ruling requires ALKS to pay $15M to cover past royalties and $1.5M as prejudgment interest to ACOR. In addition, ACOR will be free to use alternative supplies of Ampyra and will not have to pay ALKS any royalties on net sales for licensing and supplies. Also known as dalfampridine, Ampyra is marketed as Fampyra outside the U.S. by Biogen (BIIB). The extended-release tablet formulation is indicated in the U.S. to improve walking in adults with multiple sclerosis. In 2021, ACOR generated $84.6M of net revenue from Ampyra in the U.S.
Seeking Alpha • Oct 10Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on voteAcorda Therapeutics (NASDAQ:ACOR) said it withdrew a proposal requesting to increase the number of company's authorized shares. The company is scheduled to hold a special meeting of stockholders on Nov. 4, where several proposals would be put to vote. Meanwhile, a proposal for authorization of a reverse stock split remains on the ballot and the board has asked the shareholders to vote in favor of the request, the company said in an Oct. 10 press release. "However, the proposal to implement a reverse split of Acorda's stock remains critical to ensure that we can get the stock price above $1.00, which would prevent the company from being delisted by Nasdaq. If that were to occur, we could be in default on our obligations to our debtholders and may be required to declare bankruptcy or liquidate, which would be adverse to the interests of shareholders and patients," said Acorda's President and CEO Ron Cohen. ACOR +10.81% to $0.41 premarket Oct. 10
Seeking Alpha • Aug 29Acorda inks license deal with Asieris for pre-clinical drugCommercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses. In return, Acorda (ACOR) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales. Acorda (ACOR) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat. Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.
Seeking Alpha • Aug 19Acorda Therapeutics announces resignation of COOAcorda Therapeutics (NASDAQ:ACOR) has announced that Lauren Sabella, Chief Operating Officer, will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior VP, Operations & Strategic Planning and Susan Way, Senior VP, Drug Development and Regulatory Affairs. ACOR +4.35% premarket to $0.48.
Reported Earnings • Aug 05Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)Second quarter 2022 results: US$2.78 loss per share (down from US$2.29 loss in 2Q 2021). Revenue: US$31.1m (down 2.3% from 2Q 2021). Net loss: US$46.7m (loss widened 104% from 2Q 2021).
Reported Earnings • May 13First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: US$1.93 loss per share (up from US$3.53 loss in 1Q 2021). Revenue: US$22.5m (down 22% from 1Q 2021). Net loss: US$25.6m (loss narrowed 24% from 1Q 2021). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 56%.
Board Change • May 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 11Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$9.95 loss per share (up from US$12.32 loss in FY 2020). Revenue: US$129.1m (down 16% from FY 2020). Net loss: US$104.0m (loss widened 4.4% from FY 2020). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 56%.
Board Change • Dec 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: US$31.5m (down 41% from 3Q 2020). Net loss: US$27.1m (down 468% from profit in 3Q 2020).
Seeking Alpha • Oct 04Acorda Therapeutics: Managing The TransitionToday, we take our first look at Acorda Therapeutics which has two approved products on the market. One of these is seeing increasing generic competition while the other is ramping up sales. The company recently announced a significant workforce reduction to reduce costs. Can Acorda manage this transition without diluting shareholders? A full investment analysis follows in the paragraphs below.
Executive Departure • Aug 26Independent Director Barry Greene has left the companyOn the 20th of August, Barry Greene's tenure as Independent Director ended after 14.6 years in the role. As of June 2021, Barry still personally held only 213.00 shares (US$1.0k worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.
Executive Departure • Aug 26Independent Director Catherine D. Strader has left the companyOn the 22nd of August, Catherine D. Strader's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Catherine D.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.
Reported Earnings • Aug 09Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$31.8m (down 5.5% from 2Q 2020). Net loss: US$22.9m (loss widened 31% from 2Q 2020).
Seeking Alpha • Jul 24Acorda Therapeutics Continues To Maneuver For A TurnaroundAcorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years. The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket. Acorda was able to remove their debt that was due in 2021. Now, with that overhang removed, any progress made should be reflected in the share price. I update my plan for trading Acorda over the remainder of 2021 as we wait for the remaining quarterly earnings.
分析記事 • May 26Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For NowThe underwhelming share price performance of Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) in the past three years would...
Reported Earnings • May 09First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$28.9m (up 2.7% from 1Q 2020). Net loss: US$33.5m (loss widened 417% from 1Q 2020).
Major Estimate Revision • Mar 11Analysts increase revenue estimates to US$95.7mThe 2021 consensus revenue estimate increased from US$64.5m. Earning per share (EPS) estimate also saw an improvement, with analysts raising their estimates from -US$14.61 to -US$12.17 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.6% next year. The consensus price target increased from US$4.00 to US$5.00. Share price is down by 14% to US$5.39 over the past week.
分析記事 • Mar 09Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their ForecastsAcorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders will have a reason to smile today, with the covering analyst...
Reported Earnings • Mar 06Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$153.0m (down 21% from FY 2019). Net loss: US$99.6m (loss narrowed 64% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 68% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 06Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 153%. Over the next year, revenue is expected to shrink by 58% compared to a 1,454% growth forecast for the Biotechs industry in the US.
Price Target Changed • Feb 05Price target lowered to US$19.50Down from US$22.00, the current price target is an average from 3 analysts. The new target price is 172% above the current share price of US$7.16. As of last close, the stock is down 43% over the past year.
Is New 90 Day High Low • Jan 15New 90-day high: US$6.70The company is up 67% from its price of US$4.01 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.
Major Estimate Revision • Jan 15Analysts increase EPS estimates to -US$2.88The 2020 consensus revenue estimate increased from US$133.1m to US$139.5m. Analysts raised their EPS forecasts from -US$4.95 to -US$2.88 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 11% next year. The consensus price target increased from US$22.00 to US$23.00. Share price is up 53% to US$6.37 over the past week.